Cancer Research Infection and Cancer: Biology, Therapeutics, and Prevention
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
[Cancer Research 59, 542-546, February 1, 1999]
© 1999 American Association for Cancer Research
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Bertagnolo, V.
Right arrow Articles by Capitani, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bertagnolo, V.
Right arrow Articles by Capitani, S.
[Cancer Research 59, 542-546, February 1, 1999]
© 1999 American Association for Cancer Research

Advances in Brief

Phosphoinositide 3-Kinase Activity Is Essential for all-trans-Retinoic Acid-induced Granulocytic Differentiation of HL-60 Cells1

Valeria Bertagnolo, Luca Maria Neri, Marco Marchisio, Carlo Mischiati and Silvano Capitani2

Signal Transduction Unit/Laboratory of Cell Biology, Section of Human Anatomy, Department of Morphology and Embryology, University of Ferrara, Ferrara 44100 [V. B., L. M. N., M. M., C. M., S. C.]; and Consiglio Nazionale delle Ricerche Institute of Cytomorphology, Bologna 40100 [L. M. N.], Italy


   ABSTRACT
Top
 ABSTRACT
Introduction
 Materials and Methods
 Results
 Discussion
 REFERENCES
 
Phosphoinositide 3-kinase (PI 3-K) activity increases in HL-60 cells that are induced to granulocytic differentiation by all-trans-retinoic acid. Immunochemical and immunocytochemical analyses by confocal microscopy also reveal an increase in the amount of the enzyme, which is particularly evident at the nuclear level. Inhibition of PI 3-K activity by nanomolar concentrations of wortmannin and of its expression by transfection with an antisense fragment of p85{alpha} prevented the differentiative process. The data obtained indicate that PI 3-K activity plays an essential role in promoting granulocytic differentiation.


   Introduction
Top
 ABSTRACT
 Introduction
Materials and Methods
 Results
 Discussion
 REFERENCES
 
The phosphorylation of the D-3 position of the inositol ring of phosphoinositides is caused by a family of enzymes known as PI 3-Ks,3 of which the most studied, termed PI 3-K type I, is a heterodimer of a regulatory Mr 85,000 (or 55,000) protein and a p110 (reviewed in Ref. 1 ). The p85 subunit is a multidomain protein without intrinsic catalytic activity, which mediates association of the enzyme with activated tyrosine kinases (1) . Five types of p85-like regulatory subunits exist: p85{alpha}, p85ß, p55 (termed {gamma} or p55PIK), and two alternative splices of p85{alpha} (p55{alpha} and p50{alpha}; Refs. 1 and 2 ). All five interact with p110s, of which three distinct isoforms have been identified: {alpha}, ß, and {delta}. p110 is responsible for the formation of phosphoinositides with a phosphate group at the D-3 position of the inositol ring (1) . The 3-phosphoinositides are not substrates of any known PLC, are not components of the canonical phosphoinositide turnover pathway, and may themselves act as intracellular mediators rather than precursors of inositol phosphate second messengers (1) .

Increased levels of PIP3 have been detected during diverse cellular processes, including mitogenesis, indicating that PI 3-K plays a role in cell growth and transformation (1 , 3) . However, PI 3-K is activated also by factors that trigger cellular differentiation, such as nerve growth factor in PC12 cells (4) and DMSO in murine erythroleukemia (MEL) cells (5) , suggesting that PI 3-K and its lipid products may also play a role in cell maturation.

PI 3-K is present in the HL-60 promyelocytic cell line (6) , a well-established model for the study of granulocytic differentiation when the cells are treated with retinoids, which act through a nuclear receptor belonging to the transcription factor family (7) . To determine whether PI 3-K plays a role in HL-60 cell differentiation, we monitored the amount and the activity of the enzyme in whole cells during the differentiation triggered by ATRA. Here, we demonstrate that PI 3-K increases after ATRA treatment and that specific inhibition of PI 3-K activity and down-modulation of the protein prevent the differentiation of this cell line.


   Materials and Methods
Top
 ABSTRACT
 Introduction
 Materials and Methods
Results
 Discussion
 REFERENCES
 
Cell Culture and Differentiation.
HL-60 cells were cultured and differentiated as described previously (8) . Cell differentiation was quantitated as described previously (8) . We also performed an estimate of the differentiation levels by a morphological examination of the nuclear shape on 4'-6-diamidino-2-phenylindole-stained cells. At least 200 cells were counted, and the percentage of granulocytes was evaluated. After 4 days, >90% of cells were fully differentiated, with results overlapping those obtained with CD11b expression (8) .

The experiments of inhibition of PI 3-K activity were performed as follows: the cells were pretreated with 100 nM WT for 24 h and then cultured in the presence of ATRA plus WT for the indicated times. Because WT is unstable at 37°C in culture medium, it was added every 6 h to the cell culture. As controls, cells were incubated in the presence of only WT for the same times.

Preparation of Nuclei and Immunochemical Analysis.
Membrane-depleted nuclei were isolated as described previously (8) . Nuclear purity was assessed by ultrastructural analysis and marker enzyme assays, as reported previously (8 , 9) .

Proteins from the purified fractions (50 µg) were separated and blotted as described previously (8) . Polyclonal antibody against the p85 subunit of PI 3-K was purchased from Upstate Biotechnology, Inc. (Lake Placid, NY).

PI-3 K Activity Assay.
The assays of PI 3-K activity were performed on 100 µg of protein of total cells in the presence of 10 mM HEPES, 1 mM EDTA (pH 7.5), and[{gamma}-32P]ATP (10 µCi/sample). Incorporation was for 15 min at room temperature, and the reaction was stopped by the addition of chloroform, methanol, and HCl (200:100:0.75, v/v/v), followed by two washes with chloroform, methanol, and 0.6 N HCl (3:48:47, v/v/v).

The lipid-containing organic phase was resolved on oxalate-coated TLC plates (Silica Gel 60; Merck) developed in isopropanol:acetic acid:H2O (65:1:34, v/v/v).

The radiolabeled products were identified by comparison with standard lipids obtained after incubation of purified PI 3-K enzyme (generous gift of S. Volinia, Department of Morphology and Embryology, University of Ferrara) with phosphatidylinositol, phosphatidylinositol 4-phosphate, and phosphatidylinositol 4,5-bisphospate, respectively, in conditions that optimize PI 3-K activity.

Immunofluorescence Staining.
Cells in PBS were plated onto 0.1% poly-L-lysine-coated glass slides, fixed, and processed as previously described (10) . Samples were reacted with either a polyclonal (dilution, 1:80) or monoclonal (1:40) antibody directed against the Mr 85,000 subunit of PI 3-K (Upstate Biotechnology, Inc.) with identical results. Unless otherwise stated, photographs shown were obtained with monoclonal antibodies. Confocal laser scanning microscopy and image processing analysis were performed as described previously (10) .

Transfection Experiments.
In the transfection experiments, we used the plasmid pcDNA3-p85{alpha} (11) , containing a fragment of the bovine p85{alpha} cDNA (nucleotides 35–408) in sense or antisense orientation.

Exponentially growing HL-60 cells were transfected by Lipofectin carrier (Life Technologies, Inc. Paisley, United Kingdom). Briefly, 10 µg of specific plasmid DNA were mixed with 0.5 µg of pCH110 DNA (Pharmacia, Uppsala, Sweden), a plasmid DNA that constitutively expresses the ß-galactosidase gene as control of transfection efficiency, and incubated in RPMI 1640 at room temperature for 10 min in the presence of Lipofectin reagent. A total of 2 x 106 cells were collected by centrifugation, washed three times in PBS, resuspended in RPMI 1640, and mixed to the Lipofectin-DNA mixture. After 8 h of incubation at 37°C, the cells were collected by centrifugation, washed three times in PBS, resuspended in RPMI 1640 plus 10% fetal bovine serum, and grown for 48 h. After this period, the number of ß-galactosidase-positive cells was counted to determine the efficiency of transfection, which ranged between 15 and 20%. Cells were then treated or not with 1 µM ATRA for 4 days. Daily, 100,000 cells were collected and cytocentrifuged onto a glass slide to determine the differentiation rates.

Statistical Analysis.
The results were expressed as means+ SD of three or more experiments performed in duplicate. The two-tailed Student’s t test was used for statistical analysis.


   Results
Top
 ABSTRACT
 Introduction
 Materials and Methods
 Results
Discussion
 REFERENCES
 
PI 3-K changes in HL-60 cells along the ATRA-induced differentiation pathway was first examined by immunochemical analysis (Fig. 1a)Citation , which showed a significant increase of immunoreactivity in whole lysates of cells treated for 96 h with the agonist.



View larger version (21K):
[in this window]
[in a new window]
  		Fig. 1. PI 3-K in HL-60 cells induced to granulocytic differentiation by ATRA. a, Western blot analysis with anti-p85 antibody on whole cells lysates in control conditions (Lane C) and after 96 h of ATRA treatment (Lane A). b, endogenous PI 3-K activity assayed in vitro on whole cells, under control conditions (Lane C) and after 96 h of treatment with 1 µM ATRA (Lane A). PA, phosphatidic acid; PIP, phosphatidylinositol monophosphate; PIP2, phosphatidylinositol bisphospate; PIP3, phosphatidylinositol trisphosphate; OR: origin. Data are representative of four separate experiments.

 
PI 3-K activity, measured as PIP3 recovery, increased significantly after ATRA treatment (Fig. 1b)Citation . The contemporary administration of ATRA and WT, a fungal product known to inhibit agonist stimulated PI 3-K activity, largely reduced the recovery of PIP3 in both control and treated conditions (Fig. 2a)Citation . The in situ analysis by fluorescence microscopy demonstrated that the treatment with WT impaired the morphological changes of the nucleus typically observed in the granulocytic-like differentiation of HL-60 cells (Fig. 2b)Citation . Viability and cell proliferation were not affected by the administration of WT both with and without ATRA treatment, whereas the percentage of differentiated cells dramatically decreased (Fig. 2, c–e)Citation .



View larger version (64K):
[in this window]
[in a new window]
  		Fig. 2. Effect of WT on HL-60 differentiation induced by ATRA. a, PI 3-K activity before and after the administration of WT. b, morphological analysis of HL-60 cells under the different conditions (scale bar, 2 µm). c–e, evaluation of cell viability (c), cell growth (d), and percentage of differentiated cells (e) during WT administration. C, control; A, 96 h of ATRA treatment; W, 96 h of WT treatment; A W, 96 h of simultaneous ATRA plus WT administration. {diamondsuit}, C; {triangleup}, A; , W; {blacktriangleup}, A + W.

 
To further assess the role of PI 3-K in granulocytic differentiation, we transiently transfected HL-60 cells with pcDNA3-p85 containing a fragment of the p85 gene, in sense and antisense orientation. The response of the transfected cells was consistent with a PI 3-K modulation. In fact, when probed by Western blot, the amount of PI 3-K in cells transfected with the antisense construct was reduced (Fig. 3a)Citation . As expected, the percentage of cells transfected with the sense construct and differentiating after ATRA treatment overlapped that of mock-transfected cells (data not shown) and constituted the control experiment (Fig. 3b)Citation . On the contrary, ATRA treatment of cells transfected with the antisense construct resulted in a reduced number of terminally differentiated cells at all of the examined days, with an inhibition that closely reflects the percentage of transfected cells (Fig. 3b)Citation .



View larger version (31K):
[in this window]
[in a new window]
  		Fig. 3. Response to ATRA of HL-60 cells after transfection with an antisense fragment of p85. a, evaluation by Western blot analysis, on total cell lysate, of p85 expression after transfection experiments. Lane C, control conditions; Lane S, transfection with sense construct; Lane AS, transfection with antisense construct. b, effect of ATRA on the number of fully differentiated cells after transfection of HL-60 with sense and antisense constructs. p85-S (), transfection with the sense construct (control condition); p85-AS (), transfection with the antisense construct; p85-S ATRA (), transfection with the sense construct plus 96 h of ATRA treatment; p85-AS ATRA ({blacksquare}), transfection with the antisense construct plus 96 h of ATRA treatment. Columns, means of three independent experiments, expressed as percentage of fully differentiated cells on the total number of viable cells (SDs were within 5% of the means). *, a statistically (P < 0.05) significant difference between cells transfected with the antisense versus sense construct.

 
Immunochemical (Fig. 4a)Citation and confocal (Fig. 4b)Citation analysis of the subcellular distribution of PI 3-K along the differentiation process, showed that the enzyme was discretely present in both cytoplasmic and nuclear compartments. In the cytosolic fractions no significant variations were detectable at the times examined, whereas in isolated nuclei, which showed a constitutive content of p85, PI 3-K increased progressively reaching the highest levels at 96 h, in correspondence with a fully differentiated phenotype (Fig. 4a)Citation . Immunocytochemical analysis revealed the prevalence of the enzyme in the cytoplasm and confirmed a progressive increase of nuclear PI 3-K (Fig. 4b)Citation .



View larger version (45K):
[in this window]
[in a new window]
  		Fig. 4. Subcellular distribution of p85 in HL-60 cells during ATRA treatment. a, Western blot analysis on whole cell lysates (Cell), cytosol (Cyt) and nuclei (Nu) after treatment of cells with 1 µM ATRA for the indicated times (0, 24, 48, 78, and 96 h, respectively). b, PI 3-K in situ immunolocalization analyzed by confocal microscopy. Scale bar, 2 µm.

 

   Discussion
Top
 ABSTRACT
 Introduction
 Materials and Methods
 Results
 Discussion
REFERENCES
 
PI 3-K has been shown to be directly associated (via its p85 subunit) with and activated by various normal and oncogenic tyrosine kinases, suggesting that it may regulate proliferation and/or other functions of normal and neoplastic cells (12) . However, a role for PI 3-K in differentiation has also been shown. In rat PC12 cells, PI 3-K is necessary for multiple steps of neurite outgrowth during nerve growth factor-stimulated differentiation, and chronic treatment with WT inhibits the late phase of neurite extension (13) . When murine erythroleukemia cells undergo erythroid differentiation by the addition of DMSO, an increase of PI 3-K activity occurs, and WT administration delayed the differentiation process (5) . An involvement of PI 3-K in the adipocytic differentiation of 3T3-L1 cell was also reported. In this work, treatment with WT significantly inhibited adipogenesis of cells treated with isobutylmethylxanthine, dexamethasone, and insulin (14) . More recently, it has also been shown that the inhibition of PI 3-K activity by LY294002 abrogates the insulin-like growth factor I-induced enhancement of macrophage-like differentiation in HL-60 cells treated with vitamin D3 (15) .

Here, we provide biochemical and morphological evidence for a specific involvement of PI 3-K activity in HL-60 granulocytic differentiation. PI 3-K is relevant to this process because reduction of PI 3-K activity by WT prevented the effects of ATRA. Accordingly, the decrease of protein expression obtained by antisense transfection inhibited granulocytic differentiation.

Although increased PI 3-K activity was originally associated with activation of receptor tyrosine kinases, it also occurs in response to activation of receptors lacking intrinsic tyrosine kinase activity, such as interleukin 2, interleukin 3, granulocyte macrophage colony-stimulating factor, and T-cell receptors (reviewed in Ref. 3 ). Our data provide the first evidence that also an agonist with a nuclear receptor induces PI 3-K activity, which promotes differentiation.

The action of PI 3-K in ATRA-driven differentiation is conceivably mediated by the downstream targets of PI 3-K products, which include Akt (PKB), p70S6 kinase, cytoskeletal proteins (1) , and PKC {zeta} (15) . The link between PI 3-K and PKC has been recently elucidated and involves a PDK1 phosphorylation of the activation loop sites of PKC {zeta}, and PKC {delta} in a PI 3-K-dependent manner (16) . It has been recently suggested that PIP3 activates PLC {gamma}, revealing a novel mechanism for mutual regulation between these two enzymes that participate in the control of phosphoinositide metabolism (17 , 18) . Recent data also showed a cross-communication between nuclear PLC and PI 3-K pathways (19) .

The ATRA-dependent differentiation process of HL-60 induced changes not only in the cytoplasm but also in the nuclear compartment. This observation is related to our previous findings describing the nuclear translocation of PLC ß and {gamma} and of specific PKC {alpha} and {zeta} during granulocytic differentiation of HL-60 cells (8 , 20) . On the other hand, nuclear PI 3-K has been described in cells other than HL-60, such as PC12 (21) , Saos-2 (22) , and rat liver (19) cells, suggesting that translocation of this enzyme to the nucleus is a widespread occurrence.

It is worthwhile to note that different inositol lipid-modifying enzymes are recruited during granulocytic differentiation, and in particular, PI 3-K may play a relevant role in this process, as demonstrated here by inhibition and down-modulation experiments. It can be informative to explore in future if an additional modulating pathway might rely on cross-talk between different enzymes.


   ACKNOWLEDGMENTS
 
We are grateful to Lewis Cantley for helpful discussion and suggestions. We thank Wataru Ogawa (Kobe University School of Medicine, Kobe, Japan) for the plasmids used in the transfection experiments and Stefano Volinia for a generous supply of the purified PI 3-K.


   FOOTNOTES
 
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

1 This work was supported by Italian Consiglio Nazionale delle Ricerche (Progetto Finalizzato Biotecnologie), Associazione Italiana Ricerca sul Cancro, and University of Ferrara (60% funding). Back

2 To whom requests for reprints should be addressed, at Signal Transduction Unit, Department of Morphology and Embryology, Section of Human Anatomy, University of Ferrara, Via Fossato di Mortara 66, 44100 Ferrara, Italy. Phone: 39-532-291571; Fax: 39-532-207351; E-mail: cps{at}dns.unife.it Back

3 The abbreviations used are: PI 3-K, phosphoinositide 3-kinase; p110, catalytic Mr 110,000 protein subunit; PLC, phospholipase C; PIP3, phosphatidylinositol 3,4,5-trisphosphate; ATRA, all-trans-retinoic acid; WT, wortmannin; PKC, protein kinase C. Back

Received 3/27/98. Accepted 12/16/98.


   REFERENCES
Top
 ABSTRACT
 Introduction
 Materials and Methods
 Results
 Discussion
 REFERENCES
 

  1. Domin J., Waterfield M. D. Using structure to define the function of phosphoinositide 3-kinase family members. FEBS Lett., 410: 91-95, 1997.[Medline]
  2. Fruman D. A., Cantley L. C., Carpenter C. L. Structural organization and alternative splicing of the murine phosphoinositide 3-kinase p85 {alpha} gene. Genomics, 37: 113-121, 1996.[Medline]
  3. Varticovski L., Harrison Findik D., Keeler M. L., Susa M. Role of PI 3-kinase in mitogenesis. Biochim. Biophys. Acta, 1226: 1-11, 1994.[Medline]
  4. Soltoff S. P., Rabin S. L., Cantley L. C., Kaplan D. R. Nerve growth factor promotes the activation of phosphatidylinositol 3-kinase and its association with the trk tyrosine kinase. J. Biol. Chem., 267: 17472-17477, 1992.[Abstract/Free Full Text]
  5. Ai Z., Misra S., Susa M., Varticovski L., Cohen C. M. Phosphatidylinositol 3-kinase activity in murine erythroleukemia cells during DMSO-induced differentiation. Exp. Cell Res., 219: 454-460, 1995.[Medline]
  6. Volinia S., Dh R., Vanhaesebroeck B., MacDougall L. K., Stein R., Zvelebil M. J., Domin J., Panaretou C., Waterfield M. D. A human phosphatidylinositol 3-kinase complex related to the yeast Vps34p-Vps15p protein sorting system. EMBO J., 14: 3339-3348, 1995.[Medline]
  7. Chambon P. The retinoid signalling pathway: molecular and genetic analyses. Semin. Cell. Biol., 5: 115-125, 1994.[Medline]
  8. Bertagnolo V., Marchisio M., Capitani S., Neri L. M. Intranuclear translocation of phospholipase C ß2 during HL-60 myeloid differentiation. Biochem. Biophys. Res. Commun., 235: 831-837, 1997.[Medline]
  9. Martelli A. M., Gilmour R. S., Bertagnolo V., Neri L. M., Manzoli L., Cocco L. Nuclear localization and signalling activity of phosphoinositidase C ß in Swiss 3T3 cells. Nature (Lond.), 358: 242-245, 1992.[Medline]
  10. Neri L. M., Riederer B. M., Valmori A., Capitani S., Martelli A. M. Different concentrations of Mg++ ions affect nuclear matrix protein distribution during thermal stabilization of isolated nuclei. J. Histochem. Cytochem., 45: 1317-1328, 1997.[Abstract/Free Full Text]
  11. Skorski T., Kanakaraj P., Nieborowska-Skorska M., Atajczak M. Z., Shau-Chin W., Zon G., Gewirtz A. M., Perussia B., Calabretta B. Phosphatidylinositol 3-Kinase activity is regulated by BCR/ABL and is required for the growth of Philadelphia chromosome-positive cells. Blood, 86: 726-736, 1995.[Abstract/Free Full Text]
  12. Cantley L. C., Auger K. R., Carpenter C., Duckworth B., Graziani A., Kapeller R., Soltoff V. Oncogenes and signal transduction. Cell, 64: 281-302, 1991.[Medline]
  13. Kimura K., Hattori S., Kabuyama Y., Shizawa Y., Takayanagi J., Nakamura S., Toki S., Matsuda Y., Onodera K., Fukui Y. Neurite outgrowth of PC12 cells is suppressed by wortmannin, a specific inhibitor of phosphatidylinositol 3-kinase. J. Biol. Chem., 269: 18961-18967, 1994.[Abstract/Free Full Text]
  14. Tomiyama K., Nakata H., Sasa H., Arimura S., Nishio E., Watanabe Y. Wortmannin, a specific phosphatidylinositol 3-kinase inhibitor, inhibits adipocytic differentiation of 3T3—L1 cells. Biochem. Biophys. Res. Commun., 212: 263-269, 1995.[Medline]
  15. Liu Q., Ning W., Dantzer R., Freund G. G., Kelley K. W. Activation of protein kinase C-{zeta} and phosphatidylinositol 3-kinase and promotion of macrophage differentiation by insulin-like growth factor-I. J. Immunol., 160: 1393-1401, 1998.[Abstract/Free Full Text]
  16. Le , Good J. A., Ziegler W. H., Parekh D. B., Alessi D. R., Cohen P., Parker P. J. Protein kinase C isotypes controlled by phosphoinositide 3-kinase through the protein kinase PDK1. Science (Washington DC), 281: 2042-2045, 1998.[Abstract/Free Full Text]
  17. Bae Y. S., Cantley L. G., Chen C. S., Kim S. R., Kwon K. S., Rhee S. G. Activation of phospholipase C-{gamma} by phosphatidylinositol 3,4,5-trisphosphate. J. Biol. Chem., 273: 4465-4469, 1998.[Abstract/Free Full Text]
  18. Falasca M., Logan S. K., Letho V. P., Baccante G., Lemmon M. A., Schlessinger J. Activation of phospholipase C {gamma} by PI 3-kinase-induced PH domain-mediated membrane targeting. EMBO J., 17: 414-422, 1998.[Medline]
  19. Lu P. J., Hsu A. L., Wang D. S., Yan H. Y., Yin H. L., Chen C. S. Phosphoinositide 3-kinase in rat liver nuclei. Biochemistry, 37: 5738-5745, 1998.[Medline]
  20. Zauli G., Visani G., Bassini A., Caramelli E., Ottaviani E., Bertolaso L., Bertagnolo V., Borgatti P., Capitani S. Nuclear translocation of protein kinase C {alpha} and {zeta} isoforms in HL-60 cells induced to differentiate along the granulocytic lineage by all-trans retinoic acid. Br. J. Haematol., 93: 542-550, 1996.[Medline]
  21. Neri L. M., Milani D., Bertolaso L., Stroscio M., Bertagnolo V., Capitani S. Nuclear translocation of phosphatidylinositol 3-kinase in rat pheochromocytoma PC12 cells after treatment with nerve growth factor. Cell. Mol. Biol., 40: 619-626, 1994.[Medline]
  22. Zini N., Ognibene A., Bavelloni A., Santi S., Sabatelli P., Baldini N., Scotli K., Serra M., Maraldi N. M. Cytoplasmic and nuclear localization sites of phosphatidylinositol 3-kinase in human osteosarcoma sensitive and multidrug-resistant Saos-2 cells. Histochem. Cell Biol., 106: 457-464, 1996.[Medline]



This article has been cited by other articles:


Home page
 CarcinogenesisHome page
V. Bertagnolo, M. Benedusi, F. Brugnoli, P. Lanuti, M. Marchisio, P. Querzoli, and S. Capitani
Phospholipase C-{beta}2 promotes mitosis and migration of human breast cancer-derived cells
Carcinogenesis, August 1, 2007; 28(8): 1638 - 1645.
[Abstract] [Full Text] [PDF]

Home page
 Mol Cancer ResHome page
B. Ozpolat, U. Akar, M. Steiner, I. Zorrilla-Calancha, M. Tirado-Gomez, N. Colburn, M. Danilenko, S. Kornblau, and G. Lopez Berestein
Programmed Cell Death-4 Tumor Suppressor Protein Contributes to Retinoic Acid-Induced Terminal Granulocytic Differentiation of Human Myeloid Leukemia Cells
Mol. Cancer Res., January 1, 2007; 5(1): 95 - 108.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
S. H. Kim, J. H. Song, B. G. Choi, H.-J. Kim, and T. S. Kim
Chemical Modification of Santonin into a Diacetoxy Acetal Form Confers the Ability to Induce Differentiation of Human Promyelocytic Leukemia Cells via the Down-regulation of NF-{kappa}B DNA Binding Activity
J. Biol. Chem., May 12, 2006; 281(19): 13117 - 13125.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
L. Lal, Y. Li, J. Smith, A. Sassano, S. Uddin, S. Parmar, M. S. Tallman, S. Minucci, N. Hay, and L. C. Platanias
Activation of the p70 S6 kinase by all-trans-retinoic acid in acute promyelocytic leukemia cells
Blood, February 15, 2005; 105(4): 1669 - 1677.
[Abstract] [Full Text] [PDF]

Home page
 J. Leukoc. Biol.Home page
V. Bertagnolo, M. Marchisio, S. Pierpaoli, M. L. Colamussi, F. Brugnoli, G. Visani, G. Zauli, and S. Capitani
Selective up-regulation of phospholipase C-{beta}2 during granulocytic differentiation of normal and leukemic hematopoietic progenitors
J. Leukoc. Biol., June 1, 2002; 71(6): 957 - 965.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
M. A. Antonyak, J. E. Boehm, and R. A. Cerione
Phosphoinositide 3-Kinase Activity Is Required for Retinoic Acid-induced Expression and Activation of the Tissue Transglutaminase
J. Biol. Chem., April 19, 2002; 277(17): 14712 - 14716.
[Abstract] [Full Text] [PDF]

Home page
 Cell Growth Differ.Home page
V. Bertagnolo, M. Marchisio, F. Brugnoli, A. Bavelloni, L. Boccafogli, M. L. Colamussi, and S. Capitani
Requirement of Tyrosine-phosphorylated Vav for Morphological Differentiation of All-trans-Retinoic Acid-treated HL-60 Cells
Cell Growth Differ., April 1, 2001; 12(4): 193 - 200.
[Abstract] [Full Text]

Home page
 FASEB J.Home page
L. M. NERI, A. M. MARTELLI, P. BORGATTI, M. L. COLAMUSSI, M. MARCHISIO, and S. CAPITANI
Increase in nuclear phosphatidylinositol 3-kinase activity and phosphatidylinositol (3,4,5) trisphosphate synthesis precede PKC-{zeta} translocation to the nucleus of NGF-treated PC12 cells
FASEB J, December 1, 1999; 13(15): 2299 - 2310.
[Abstract] [Full Text]

Home page
 J. Biol. Chem.Home page
C. S. T. Hii, N. Moghadammi, A. Dunbar, and A. Ferrante
Activation of the Phosphatidylinositol 3-Kinase-Akt/Protein Kinase B Signaling Pathway in Arachidonic Acid-stimulated Human Myeloid and Endothelial Cells. INVOLVEMENT OF THE ErbB RECEPTOR FAMILY
J. Biol. Chem., July 13, 2001; 276(29): 27246 - 27255.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Bertagnolo, V.
Right arrow Articles by Capitani, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bertagnolo, V.
Right arrow Articles by Capitani, S.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online